Serum Surfactant Protein D as a Prognostic Factor in Idiopathic Pulmonary Fibrosis Patients | ||||
Bulletin of Egyptian Society for Physiological Sciences | ||||
Article 14, Volume 31, Issue 2, June 2011, Page 179-190 PDF (356.68 K) | ||||
Document Type: Original Article | ||||
DOI: 10.21608/besps.2011.36136 | ||||
View on SCiNiTO | ||||
Authors | ||||
Dawlat El-Miligy* 1; Laila Rashed2; M Wafai3; Haidi Abu-Hussein1 | ||||
1Medical Biochemistry Department, Faculty of Medicine, October 6 University | ||||
2Medical Biochemistry Department, Faculty of Medicine, Cairo University | ||||
3Chest Diseases Department, Faculty of Medicine, Cairo University | ||||
Abstract | ||||
Idiopathic pulmonary fibrosis (IPF) carries a 50% 5-years survival rate. The pathogenesis of IPF is characterized by chronic inflammation, fibroblast proliferation and extracellular matrix production with chronic scarring and honeycomb formation. This fibroproliferative response is uniformly accompanied by type II cell hyperplasia. Surfactant proteins–D (SP-D), is produced and secreted by type II cells. It can be detected in serum and is elevated in patients with certain inflammatory lung diseases. Measurement of this protein might be a useful marker for early detection of IPF and its prognosis. The present work was conducted on 30 patients, and 10 healthy volunteers obtained from chest Department, Faculty of Medicine, Cairo University, and were categorized into four groups as follows: Group 1: Included ten healthy volunteers as control group, Group 2: Consists of ten patients with idiopathic pulmonary fibrosis (IPF) received steroid therapy for one month, Group 3: Ten patients with idiopathic pulmonary fibrosis (IPF) not receiving steroid therapy and Group 4: Included ten patients with chronic chest disease without idiopathic pulmonary fibrosis. All groups were subjected to history taking, pulmonary function test and estimation of serum surfactant D (SP-D level) by ELISA. The results of the present study showed significant decrease in the pulmonary function tests represented by forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) (FEV1/FVC%) in the three diseased groups compared to control. Mean level of SP-D in serum showed a highly significant increase in the three diseased groups compared to control. The mean level of serum SP-D is significantly higher in group 3 compared to group 2. Furthermore, significant negative correlation was found between SP-D serum level and FEV1 and FEV1/FVC in all IPF patients. From these results it could be concluded that the SP-D assay may be of value in estimating the rate of decline in pulmonary function in cases of IPF as well as in the follow up of disease progress. It may also assist in making clinical choices for therapeutic management of these patients. | ||||
Statistics Article View: 73 PDF Download: 85 |
||||